On Nov. 10, 2020, Oxford Immunotec announced the release of data from a prospective cohort study in keyworkers in the UK ﾖ a collaboration between the Company and Public Health England (PHE). The data demonstrated that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.